Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone408-720-9002
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$34.56 million
Profitability
Miscellaneous
Employees176
Next Earnings Date2/26/2020 (Confirmed)
OptionableNot Optionable
Silk Road Medical (NASDAQ:SILK) Frequently Asked Questions
What is Silk Road Medical's stock symbol?
Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."
How were Silk Road Medical's earnings last quarter?
Silk Road Medical Inc (NASDAQ:SILK) announced its earnings results on Tuesday, October, 29th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The firm earned $17 million during the quarter, compared to analyst estimates of $15.93 million. Silk Road Medical's revenue for the quarter was up 77.1% on a year-over-year basis. View Silk Road Medical's Earnings History.
When is Silk Road Medical's next earnings date?
How can I listen to Silk Road Medical's earnings call?
Silk Road Medical will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for SILK?
5 Wall Street analysts have issued 12 month target prices for Silk Road Medical's shares. Their forecasts range from $40.01 to $52.00. On average, they expect Silk Road Medical's stock price to reach $44.80 in the next twelve months. This suggests that the stock has a possible downside of 4.7%. View Analyst Price Targets for Silk Road Medical.
What is the consensus analysts' recommendation for Silk Road Medical?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silk Road Medical.
Has Silk Road Medical been receiving favorable news coverage?
Media coverage about SILK stock has trended very positive this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Silk Road Medical earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View News Stories for Silk Road Medical.
Are investors shorting Silk Road Medical?
Silk Road Medical saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,220,000 shares, a decrease of 6.2% from the January 15th total of 1,300,000 shares. Based on an average daily trading volume, of 331,100 shares, the short-interest ratio is presently 3.7 days. Currently, 6.0% of the company's stock are sold short. View Silk Road Medical's Current Options Chain.
Who are some of Silk Road Medical's key competitors?
Some companies that are related to Silk Road Medical include Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), ICU Medical (ICUI), Nevro (NVRO), NuVasive (NUVA), Cantel Medical (CMD), Glaukos (GKOS), Irhythm Technologies (IRTC), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), AtriCure (ATRC), Cardiovascular Systems (CSII), Atrion (ATRI) and Shockwave Medical (SWAV).
What other stocks do shareholders of Silk Road Medical own?
Who are Silk Road Medical's key executives?
Silk Road Medical's management team includes the folowing people:
- Ms. Erica J. Rogers, Chief Exec. Officer, Pres & Director (Age 55)
- Mr. Lucas W. Buchanan, Chief Financial Officer (Age 41)
- Mr. Robert A. Nicholas, VP of Operations & Engineering (Age 56)
- Mr. Andrew S. Davis, Exec. VP of Global Sales & Marketing (Age 50)
- Ms. Alison Highlander, VP of HR
When did Silk Road Medical IPO?
(SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.
Who are Silk Road Medical's major shareholders?
Silk Road Medical's stock is owned by many different of retail and institutional investors. Top institutional investors include Warburg Pincus LLC (19.13%), Janus Henderson Group PLC (6.25%), Alliancebernstein L.P. (4.73%), Bamco Inc. NY (4.41%), Jennison Associates LLC (3.97%) and Victory Capital Management Inc. (2.48%). Company insiders that own Silk Road Medical stock include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg, Richard Ruedy and X Finance LP Wp. View Institutional Ownership Trends for Silk Road Medical.
Which institutional investors are selling Silk Road Medical stock?
SILK stock was sold by a variety of institutional investors in the last quarter, including Warburg Pincus LLC, Janus Henderson Group PLC, Lord Abbett & CO. LLC, Schonfeld Strategic Advisors LLC, Credit Suisse AG, Nicholas Investment Partners LP, ArrowMark Colorado Holdings LLC and Advisor Group Inc.. Company insiders that have sold Silk Road Medical company stock in the last year include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg, Richard Ruedy and X Finance LP Wp. View Insider Buying and Selling for Silk Road Medical.
Which institutional investors are buying Silk Road Medical stock?
SILK stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Alliancebernstein L.P., Cannell Peter B & Co. Inc., Parkman Healthcare Partners LLC, Jennison Associates LLC, Sectoral Asset Management Inc, Bamco Inc. NY and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Silk Road Medical.
How do I buy shares of Silk Road Medical?
Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Silk Road Medical's stock price today?
One share of SILK stock can currently be purchased for approximately $46.99.
How big of a company is Silk Road Medical?
What is Silk Road Medical's official website?
How can I contact Silk Road Medical?
Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company can be reached via phone at 408-720-9002 or via email at [email protected]
MarketBeat Community Rating for Silk Road Medical (NASDAQ SILK)
MarketBeat's community ratings are surveys of what our community members think about Silk Road Medical and other stocks. Vote "Outperform" if you believe SILK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SILK will underperform the S&P 500 over the long term. You may vote once every thirty days.
